- Home
- GORV vs CANF Comparison
GORV vs CANF Comparison
Compare GORV & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- CANF
- Stock Information
- Founded
- GORV 1976
- CANF 1994
- Country
- GORV United States
- CANF Israel
- Employees
- GORV N/A
- CANF N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- CANF Health Care
- Exchange
- GORV Nasdaq
- CANF Nasdaq
- Market Cap
- GORV 10.6M
- CANF 9.6M
- IPO Year
- GORV 2015
- CANF N/A
- Fundamental
- Price
- GORV $3.06
- CANF $0.65
- Analyst Decision
- GORV
- CANF Strong Buy
- Analyst Count
- GORV 0
- CANF 2
- Target Price
- GORV N/A
- CANF $14.50
- AVG Volume (30 Days)
- GORV 950.5K
- CANF 165.4K
- Earning Date
- GORV 08-14-2025
- CANF 08-26-2025
- Dividend Yield
- GORV N/A
- CANF N/A
- EPS Growth
- GORV N/A
- CANF N/A
- EPS
- GORV N/A
- CANF N/A
- Revenue
- GORV $662,952,000.00
- CANF $560,000.00
- Revenue This Year
- GORV $15.65
- CANF $461.72
- Revenue Next Year
- GORV $20.54
- CANF N/A
- P/E Ratio
- GORV N/A
- CANF N/A
- Revenue Growth
- GORV N/A
- CANF N/A
- 52 Week Low
- GORV $2.22
- CANF $0.63
- 52 Week High
- GORV $58.80
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- GORV 43.41
- CANF 35.66
- Support Level
- GORV $2.30
- CANF $0.64
- Resistance Level
- GORV $2.89
- CANF $0.68
- Average True Range (ATR)
- GORV 0.60
- CANF 0.02
- MACD
- GORV 0.08
- CANF 0.01
- Stochastic Oscillator
- GORV 18.67
- CANF 42.50
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).